LPI (LP Information)' newest research report, the “Molecular Diagnostics in Point of Care Industry Forecast” looks at past sales and reviews total world Molecular Diagnostics in Point of Care sales in 2022, providing a comprehensive analysis by region and market sector of projected Molecular Diagnostics in Point of Care sales for 2023 through 2029. With Molecular Diagnostics in Point of Care sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Molecular Diagnostics in Point of Care industry.
This Insight Report provides a comprehensive analysis of the global Molecular Diagnostics in Point of Care landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Molecular Diagnostics in Point of Care portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Molecular Diagnostics in Point of Care market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Molecular Diagnostics in Point of Care and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Molecular Diagnostics in Point of Care.
The global Molecular Diagnostics in Point of Care market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Molecular Diagnostics in Point of Care is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Molecular Diagnostics in Point of Care is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Molecular Diagnostics in Point of Care is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Molecular Diagnostics in Point of Care players cover Abbott, Accelerate Diagnostics, Ador Diagnostics, Beckman Coulter, Becton, Dickinson and Company, Binx Health, Biocartis, bioMérieux and Bio-Rad Laboratories, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Molecular Diagnostics in Point of Care market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
Polymerase Chain Reaction
In Situ Hybridization
Gene Chips
Next Generation Sequencing
Segmentation by application
Hospitals and Clinics
Independent Clinical Laboratories
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Abbott
Accelerate Diagnostics
Ador Diagnostics
Beckman Coulter
Becton, Dickinson and Company
Binx Health
Biocartis
bioMérieux
Bio-Rad Laboratories
Bosch Healthcare Solutions
Curetis
Eurofins Scientific
Genetic Signatures
Grifols
Hibergene Diagnostics
Lumos Diagnostics
Roche
Siemens
Thermo Fisher Scientific

1 Scope of the Report 1.1 Market Introduction 1.2 Years Considered 1.3 Research Objectives 1.4 Market Research Methodology 1.5 Research Process and Data Source 1.6 Economic Indicators 1.7 Currency Considered 1.8 Market Estimation Caveats 2 Executive Summary 2.1 World Market Overview 2.1.1 Global Molecular Diagnostics in Point of Care Market Size 2018-2029 2.1.2 Molecular Diagnostics in Point of Care Market Size CAGR by Region 2018 VS 2022 VS 2029 2.2 Molecular Diagnostics in Point of Care Segment by Type 2.2.1 Polymerase Chain Reaction 2.2.2 In Situ Hybridization 2.2.3 Gene Chips 2.2.4 Next Generation Sequencing 2.3 Molecular Diagnostics in Point of Care Market Size by Type 2.3.1 Molecular Diagnostics in Point of Care Market Size CAGR by Type (2018 VS 2022 VS 2029) 2.3.2 Global Molecular Diagnostics in Point of Care Market Size Market Share by Type (2018-2023) 2.4 Molecular Diagnostics in Point of Care Segment by Application 2.4.1 Hospitals and Clinics 2.4.2 Independent Clinical Laboratories 2.5 Molecular Diagnostics in Point of Care Market Size by Application 2.5.1 Molecular Diagnostics in Point of Care Market Size CAGR by Application (2018 VS 2022 VS 2029) 2.5.2 Global Molecular Diagnostics in Point of Care Market Size Market Share by Application (2018-2023) 3 Molecular Diagnostics in Point of Care Market Size by Player 3.1 Molecular Diagnostics in Point of Care Market Size Market Share by Players 3.1.1 Global Molecular Diagnostics in Point of Care Revenue by Players (2018-2023) 3.1.2 Global Molecular Diagnostics in Point of Care Revenue Market Share by Players (2018-2023) 3.2 Global Molecular Diagnostics in Point of Care Key Players Head office and Products Offered 3.3 Market Concentration Rate Analysis 3.3.1 Competition Landscape Analysis 3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2021-2023) 3.4 New Products and Potential Entrants 3.5 Mergers & Acquisitions, Expansion 4 Molecular Diagnostics in Point of Care by Regions 4.1 Molecular Diagnostics in Point of Care Market Size by Regions (2018-2023) 4.2 Americas Molecular Diagnostics in Point of Care Market Size Growth (2018-2023) 4.3 APAC Molecular Diagnostics in Point of Care Market Size Growth (2018-2023) 4.4 Europe Molecular Diagnostics in Point of Care Market Size Growth (2018-2023) 4.5 Middle East & Africa Molecular Diagnostics in Point of Care Market Size Growth (2018-2023) 5 Americas 5.1 Americas Molecular Diagnostics in Point of Care Market Size by Country (2018-2023) 5.2 Americas Molecular Diagnostics in Point of Care Market Size by Type (2018-2023) 5.3 Americas Molecular Diagnostics in Point of Care Market Size by Application (2018-2023) 5.4 United States 5.5 Canada 5.6 Mexico 5.7 Brazil 6 APAC 6.1 APAC Molecular Diagnostics in Point of Care Market Size by Region (2018-2023) 6.2 APAC Molecular Diagnostics in Point of Care Market Size by Type (2018-2023) 6.3 APAC Molecular Diagnostics in Point of Care Market Size by Application (2018-2023) 6.4 China 6.5 Japan 6.6 Korea 6.7 Southeast Asia 6.8 India 6.9 Australia 7 Europe 7.1 Europe Molecular Diagnostics in Point of Care by Country (2018-2023) 7.2 Europe Molecular Diagnostics in Point of Care Market Size by Type (2018-2023) 7.3 Europe Molecular Diagnostics in Point of Care Market Size by Application (2018-2023) 7.4 Germany 7.5 France 7.6 UK 7.7 Italy 7.8 Russia 8 Middle East & Africa 8.1 Middle East & Africa Molecular Diagnostics in Point of Care by Region (2018-2023) 8.2 Middle East & Africa Molecular Diagnostics in Point of Care Market Size by Type (2018-2023) 8.3 Middle East & Africa Molecular Diagnostics in Point of Care Market Size by Application (2018-2023) 8.4 Egypt 8.5 South Africa 8.6 Israel 8.7 Turkey 8.8 GCC Countries 9 Market Drivers, Challenges and Trends 9.1 Market Drivers & Growth Opportunities 9.2 Market Challenges & Risks 9.3 Industry Trends 10 Global Molecular Diagnostics in Point of Care Market Forecast 10.1 Global Molecular Diagnostics in Point of Care Forecast by Regions (2024-2029) 10.1.1 Global Molecular Diagnostics in Point of Care Forecast by Regions (2024-2029) 10.1.2 Americas Molecular Diagnostics in Point of Care Forecast 10.1.3 APAC Molecular Diagnostics in Point of Care Forecast 10.1.4 Europe Molecular Diagnostics in Point of Care Forecast 10.1.5 Middle East & Africa Molecular Diagnostics in Point of Care Forecast 10.2 Americas Molecular Diagnostics in Point of Care Forecast by Country (2024-2029) 10.2.1 United States Molecular Diagnostics in Point of Care Market Forecast 10.2.2 Canada Molecular Diagnostics in Point of Care Market Forecast 10.2.3 Mexico Molecular Diagnostics in Point of Care Market Forecast 10.2.4 Brazil Molecular Diagnostics in Point of Care Market Forecast 10.3 APAC Molecular Diagnostics in Point of Care Forecast by Region (2024-2029) 10.3.1 China Molecular Diagnostics in Point of Care Market Forecast 10.3.2 Japan Molecular Diagnostics in Point of Care Market Forecast 10.3.3 Korea Molecular Diagnostics in Point of Care Market Forecast 10.3.4 Southeast Asia Molecular Diagnostics in Point of Care Market Forecast 10.3.5 India Molecular Diagnostics in Point of Care Market Forecast 10.3.6 Australia Molecular Diagnostics in Point of Care Market Forecast 10.4 Europe Molecular Diagnostics in Point of Care Forecast by Country (2024-2029) 10.4.1 Germany Molecular Diagnostics in Point of Care Market Forecast 10.4.2 France Molecular Diagnostics in Point of Care Market Forecast 10.4.3 UK Molecular Diagnostics in Point of Care Market Forecast 10.4.4 Italy Molecular Diagnostics in Point of Care Market Forecast 10.4.5 Russia Molecular Diagnostics in Point of Care Market Forecast 10.5 Middle East & Africa Molecular Diagnostics in Point of Care Forecast by Region (2024-2029) 10.5.1 Egypt Molecular Diagnostics in Point of Care Market Forecast 10.5.2 South Africa Molecular Diagnostics in Point of Care Market Forecast 10.5.3 Israel Molecular Diagnostics in Point of Care Market Forecast 10.5.4 Turkey Molecular Diagnostics in Point of Care Market Forecast 10.5.5 GCC Countries Molecular Diagnostics in Point of Care Market Forecast 10.6 Global Molecular Diagnostics in Point of Care Forecast by Type (2024-2029) 10.7 Global Molecular Diagnostics in Point of Care Forecast by Application (2024-2029) 11 Key Players Analysis 11.1 Abbott 11.1.1 Abbott Company Information 11.1.2 Abbott Molecular Diagnostics in Point of Care Product Offered 11.1.3 Abbott Molecular Diagnostics in Point of Care Revenue, Gross Margin and Market Share (2018-2023) 11.1.4 Abbott Main Business Overview 11.1.5 Abbott Latest Developments 11.2 Accelerate Diagnostics 11.2.1 Accelerate Diagnostics Company Information 11.2.2 Accelerate Diagnostics Molecular Diagnostics in Point of Care Product Offered 11.2.3 Accelerate Diagnostics Molecular Diagnostics in Point of Care Revenue, Gross Margin and Market Share (2018-2023) 11.2.4 Accelerate Diagnostics Main Business Overview 11.2.5 Accelerate Diagnostics Latest Developments 11.3 Ador Diagnostics 11.3.1 Ador Diagnostics Company Information 11.3.2 Ador Diagnostics Molecular Diagnostics in Point of Care Product Offered 11.3.3 Ador Diagnostics Molecular Diagnostics in Point of Care Revenue, Gross Margin and Market Share (2018-2023) 11.3.4 Ador Diagnostics Main Business Overview 11.3.5 Ador Diagnostics Latest Developments 11.4 Beckman Coulter 11.4.1 Beckman Coulter Company Information 11.4.2 Beckman Coulter Molecular Diagnostics in Point of Care Product Offered 11.4.3 Beckman Coulter Molecular Diagnostics in Point of Care Revenue, Gross Margin and Market Share (2018-2023) 11.4.4 Beckman Coulter Main Business Overview 11.4.5 Beckman Coulter Latest Developments 11.5 Becton, Dickinson and Company 11.5.1 Becton, Dickinson and Company Company Information 11.5.2 Becton, Dickinson and Company Molecular Diagnostics in Point of Care Product Offered 11.5.3 Becton, Dickinson and Company Molecular Diagnostics in Point of Care Revenue, Gross Margin and Market Share (2018-2023) 11.5.4 Becton, Dickinson and Company Main Business Overview 11.5.5 Becton, Dickinson and Company Latest Developments 11.6 Binx Health 11.6.1 Binx Health Company Information 11.6.2 Binx Health Molecular Diagnostics in Point of Care Product Offered 11.6.3 Binx Health Molecular Diagnostics in Point of Care Revenue, Gross Margin and Market Share (2018-2023) 11.6.4 Binx Health Main Business Overview 11.6.5 Binx Health Latest Developments 11.7 Biocartis 11.7.1 Biocartis Company Information 11.7.2 Biocartis Molecular Diagnostics in Point of Care Product Offered 11.7.3 Biocartis Molecular Diagnostics in Point of Care Revenue, Gross Margin and Market Share (2018-2023) 11.7.4 Biocartis Main Business Overview 11.7.5 Biocartis Latest Developments 11.8 bioMérieux 11.8.1 bioMérieux Company Information 11.8.2 bioMérieux Molecular Diagnostics in Point of Care Product Offered 11.8.3 bioMérieux Molecular Diagnostics in Point of Care Revenue, Gross Margin and Market Share (2018-2023) 11.8.4 bioMérieux Main Business Overview 11.8.5 bioMérieux Latest Developments 11.9 Bio-Rad Laboratories 11.9.1 Bio-Rad Laboratories Company Information 11.9.2 Bio-Rad Laboratories Molecular Diagnostics in Point of Care Product Offered 11.9.3 Bio-Rad Laboratories Molecular Diagnostics in Point of Care Revenue, Gross Margin and Market Share (2018-2023) 11.9.4 Bio-Rad Laboratories Main Business Overview 11.9.5 Bio-Rad Laboratories Latest Developments 11.10 Bosch Healthcare Solutions 11.10.1 Bosch Healthcare Solutions Company Information 11.10.2 Bosch Healthcare Solutions Molecular Diagnostics in Point of Care Product Offered 11.10.3 Bosch Healthcare Solutions Molecular Diagnostics in Point of Care Revenue, Gross Margin and Market Share (2018-2023) 11.10.4 Bosch Healthcare Solutions Main Business Overview 11.10.5 Bosch Healthcare Solutions Latest Developments 11.11 Curetis 11.11.1 Curetis Company Information 11.11.2 Curetis Molecular Diagnostics in Point of Care Product Offered 11.11.3 Curetis Molecular Diagnostics in Point of Care Revenue, Gross Margin and Market Share (2018-2023) 11.11.4 Curetis Main Business Overview 11.11.5 Curetis Latest Developments 11.12 Eurofins Scientific 11.12.1 Eurofins Scientific Company Information 11.12.2 Eurofins Scientific Molecular Diagnostics in Point of Care Product Offered 11.12.3 Eurofins Scientific Molecular Diagnostics in Point of Care Revenue, Gross Margin and Market Share (2018-2023) 11.12.4 Eurofins Scientific Main Business Overview 11.12.5 Eurofins Scientific Latest Developments 11.13 Genetic Signatures 11.13.1 Genetic Signatures Company Information 11.13.2 Genetic Signatures Molecular Diagnostics in Point of Care Product Offered 11.13.3 Genetic Signatures Molecular Diagnostics in Point of Care Revenue, Gross Margin and Market Share (2018-2023) 11.13.4 Genetic Signatures Main Business Overview 11.13.5 Genetic Signatures Latest Developments 11.14 Grifols 11.14.1 Grifols Company Information 11.14.2 Grifols Molecular Diagnostics in Point of Care Product Offered 11.14.3 Grifols Molecular Diagnostics in Point of Care Revenue, Gross Margin and Market Share (2018-2023) 11.14.4 Grifols Main Business Overview 11.14.5 Grifols Latest Developments 11.15 Hibergene Diagnostics 11.15.1 Hibergene Diagnostics Company Information 11.15.2 Hibergene Diagnostics Molecular Diagnostics in Point of Care Product Offered 11.15.3 Hibergene Diagnostics Molecular Diagnostics in Point of Care Revenue, Gross Margin and Market Share (2018-2023) 11.15.4 Hibergene Diagnostics Main Business Overview 11.15.5 Hibergene Diagnostics Latest Developments 11.16 Lumos Diagnostics 11.16.1 Lumos Diagnostics Company Information 11.16.2 Lumos Diagnostics Molecular Diagnostics in Point of Care Product Offered 11.16.3 Lumos Diagnostics Molecular Diagnostics in Point of Care Revenue, Gross Margin and Market Share (2018-2023) 11.16.4 Lumos Diagnostics Main Business Overview 11.16.5 Lumos Diagnostics Latest Developments 11.17 Roche 11.17.1 Roche Company Information 11.17.2 Roche Molecular Diagnostics in Point of Care Product Offered 11.17.3 Roche Molecular Diagnostics in Point of Care Revenue, Gross Margin and Market Share (2018-2023) 11.17.4 Roche Main Business Overview 11.17.5 Roche Latest Developments 11.18 Siemens 11.18.1 Siemens Company Information 11.18.2 Siemens Molecular Diagnostics in Point of Care Product Offered 11.18.3 Siemens Molecular Diagnostics in Point of Care Revenue, Gross Margin and Market Share (2018-2023) 11.18.4 Siemens Main Business Overview 11.18.5 Siemens Latest Developments 11.19 Thermo Fisher Scientific 11.19.1 Thermo Fisher Scientific Company Information 11.19.2 Thermo Fisher Scientific Molecular Diagnostics in Point of Care Product Offered 11.19.3 Thermo Fisher Scientific Molecular Diagnostics in Point of Care Revenue, Gross Margin and Market Share (2018-2023) 11.19.4 Thermo Fisher Scientific Main Business Overview 11.19.5 Thermo Fisher Scientific Latest Developments 12 Research Findings and Conclusion